|
1
|
Yin X, Wang P, Yang T, Li G, Teng X, Huang W and Yu H: Identification of key modules and genes associated with breast cancer prognosis using WGCNA and ceRNA network analysis. Aging (Albany NY). 13:2519–2538. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fahad Ullah M: Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol. 1152:51–64. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C and Foti M: Deciphering miRNAs' action through miRNA editing. Int J Mol Sci. 20:62492019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen M, Chen C, Luo H, Ren J, Dai Q, Hu W, Zhou K, Tang X and Li X: MicroRNA-296-5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial-mesenchymal transition. Cell Mol Biol Lett. 25:492020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Z, Luo L, Xiang Q, Wang J, Liu Y, Deng Y and Zhao Z: MiRNA-671-5p promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis. Cell Death Dis. 11:9492020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vinchure OS and Kulshreshtha R: miR-490: A potential biomarker and therapeutic target in cancer and other diseases. J Cell Physiol. 236:3178–3193. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu H, Mu X, Liu L, Wu H, Hu X, Chen L, Liu J, Mu Y, Yuan F, Liu W and Zhao Y: Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 11:8012020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jamali L, Tofigh R, Tutunchi S, Panahi G, Borhani F, Akhavan S, Nourmohammadi P, Ghaderian SMH, Rasouli M and Mirzaei H: Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol. 233:8538–8550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng H, Gu ZY, Li Q, Liu QH, Yang XY and Zhang JJ: Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res. 12:352019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wössner N, Alhalabi Z, González J, Swyter S, Gan J, Schmidtkunz K, Zhang L, Vaquero A, Ovaa H, Einsle O, et al: Sirtuin 1 inhibiting thiocyanates (S1th)-a new class of isotype selective inhibitors of NAD+ dependent lysine deacetylases. Front Oncol. 10:6572020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rouleau S, Glouzon JS, Brumwell A, Bisaillon M and Perreault JP: 3′UTR G-quadruplexes regulate miRNA binding. RNA. 23:1172–1179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen L, Heikkinen L, Wang C, Yang Y, Sun H and Wong G: Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 20:1836–1852. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao T and Zhen XC: Dysregulation of miRNA and its potential therapeutic application in schizophrenia. CNS Neurosci Ther. 24:586–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Linna-Kuosmanen S, Bosch V, Moreau P, Moreau PR, Bouvy-Liivrand M, Niskanen H, Kansanen E, Kivelä A, Hartikainen J, Hippeläinen M, et al: NRF2 is a key regulator of endothelial microRNA expression under proatherogenic stimuli. Cardiovasc Res. 117:1339–1357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen WX, Zhou J, Zhou SS, Zhang YD, Ji TY, Zhang XL, Wang SM, Du T and Ding DG: Microvesicles derived from human Wharton's jelly mesenchymal stem cells enhance autophagy and ameliorate acute lung injury via delivery of miR-100. Stem Cell Res Ther. 11:1132020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Hu L, Huang H, Yu Y, Wang J, Yu Y, Li K, Li Y, Tian T and Chen F: CAR (CARSKNKDC) peptide modified ReNcell-derived extracellular vesicles as a novel therapeutic agent for targeted pulmonary hypertension therapy. Hypertension. 76:1147–1160. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rashed WM, Hamza MM, Matboli M and Salem SI: MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: A systematic review. Cancer Metastasis Rev. 38:771–782. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo P, Jiang C, Ji P, Wang M and Xu J: Exosomes of stem cells from human exfoliated deciduous teeth as an anti-inflammatory agent in temporomandibular joint chondrocytes via miR-100-5p/mTOR. Stem Cell Res Ther. 10:2162019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alrfaei BM, Clark P, Vemuganti R and Kuo JS: MicroRNA miR-100 decreases glioblastoma growth by targeting SMARCA5 and ErbB3 in tumor-initiating cells. Technol Cancer Res Treat. 19:15330338209607482020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang C, Qin X, Zhao N, Jin H, Zhang S and Yang H: MicroRNA-100 functions as a tumor suppressor in cervical cancer via downregulating the SATB1 expression and regulating AKT/mTOR signaling pathway and epithelial-to-mesenchymal transition. Oncol Lett. 20:1336–1344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gebeshuber CA and Martinez J: miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene. 32:3306–3310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang Q, He M, Guan S, Ma M, Wu H, Yu Z, Jiang L, Wang Y, Zong X, Jin F and Wei M: MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway. Tumour Biol. 37:5001–5011. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steber HS, Gallante C, O'Brien S, Chiu PL and Mangone M: The C. elegans 3′UTRome v2 resource for studying mRNA cleavage and polyadenylation, 3′-UTR biology, and miRNA targeting. Genome Res. 29:2104–2116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horimoto Y, Sasahara N, Sasaki R, Hlaing MT, Sakaguchi A, Saeki H, Arakawa A, Himuro T and Saito M: High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast Cancer Res Treat. 183:41–48. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, et al: FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci USA. 116:26823–26834. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jing X, Liang H, Hao C, Hongxia L and Cui X: Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer. Aging (Albany NY). 11:7442–7456. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Petrelli A, Bellomo S, Sarotto I, Kubatzki F, Sgandurra P, Maggiorotto F, Di Virgilio MR, Ponzone R, Geuna E, Galizia D, et al: MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. ESMO Open. 5:e0009372020. View Article : Google Scholar : PubMed/NCBI
|
